# Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

> **NCT05724108** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 94 (estimated)

## Conditions studied

- Metastatic Neuroendocrine Tumor

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Lutetium Lu 177 Dotatate
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Triapine

## Key facts

- **NCT ID:** NCT05724108
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-30
- **Primary completion:** 2026-12-09
- **Final completion:** 2026-12-09
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724108, "Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT05724108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*